Newborn screening system: Safety, technology, advocacy

Newborn screening (NBS) is more than 50 years old and has proven to be a powerful and successful public health system. NBS must be regarded as a system and not simply as a test. We need to work as a community to improve the culture of safety for the NBS system and thereby to reduce the risk of babies being missed by the NBS system. Adding new technologies will not prevent system failures; that will require adherence to the culture of safety. Some have argued that every newborn should have their genome sequenced at birth and this sequencing could be part of NBS. However, NBS has depended on biomarker phenotypes throughout its history and our understanding of the relationships between genotype and phenotype is imperfect. Therefore, we should avoid being seduced by genomic sequencing technology and continue to focus on phenotypic biomarkers in NBS. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

Newborn screening has a history of over 50 years and should be viewed as a complete system rather than just a test. Improving safety culture and reducing the risk of missed screenings requires a community effort, and cannot solely rely on new technologies. It is important to focus on biomarkers rather than being solely seduced by genomic sequencing technology.